RNAZ
TransCode Therapeutics Inc

7,415
Loading...
Loading...
News
all
press releases
TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside
TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns.
Stocktwits·5mo ago
News Placeholder
More News
News Placeholder
TransCode Therapeutics, Inc. Announces Results of Special Meeting
TransCode Therapeutics, Inc. Announces Results of Special Meeting TransCode Therapeutics, Inc. Announces Results of Special Meeting PR Newswire BOSTON, Feb. 25, 2025 BOSTON, Feb. 25, 2025...
PR Newswire·7mo ago
News Placeholder
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead...
PR Newswire·8mo ago
News Placeholder
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and...
PR Newswire·8mo ago
News Placeholder
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead...
PR Newswire·9mo ago
News Placeholder
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing...
PR Newswire·9mo ago
News Placeholder
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial TransCode Therapeutics...
PR Newswire·10mo ago
News Placeholder
Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered
TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders. read more...
Benzinga·1y ago
News Placeholder
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Medical oncologist brings over 25 years of industry experience to lead Clinical Development StrategyBOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA...
Globe Newswire·2y ago
News Placeholder
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported...
Globe Newswire·2y ago

Latest RNAZ News

View

Advertisement|Remove ads.

Advertisement|Remove ads.